Short Attack — velZ +5.02 · age 103w×0.45 · 24.99%
Earnings Headwind — ER in 24.489d · w1 med -2.7% (mag 1/3) · winRate 37.0% (rel 1/3) · n46
About Rocket Pharmaceuticals Inc
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States. It develops in vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), whic… Read full Trend Edge analysis →
Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ
IPO Date: February 18, 2015
Headquarters: 9 Cedarbrook Drive, Cranbury, NJ, United States, 08512
Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.
Timeframe
SMA
Value
Trend Context
Weekly
10-Week SMA
$3.28
Near-term / short-term trend
Weekly
40-Week SMA
$3.55
Medium-term trend
Weekly
80-Week SMA
$4.76
Cyclical trend (business cycle)
Weekly
200-Week SMA
$14.15
Secular trend (multi-year)
Monthly
10-Month SMA
$3.67
Near-term monthly trend
Monthly
20-Month SMA
$4.91
Medium-term monthly trend
Monthly
40-Month SMA
$13.11
Secular monthly trend
Volume Shelves — Support & Resistance
Trend Edge identifies volume shelves: price zones where historically elevated trading volume
creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative
volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.
Price Level
Type
Volume Ratio
Age
$4.90
resistance
1.63x
3 months ago
$2.50
support
1.30x
11 months ago
$7.60
resistance
3.39x
13 months ago
$9.40
resistance
1.59x
15 months ago
$12.80
resistance
1.58x
17 months ago
Historical Earnings Reactions (46 events)
Timeframe
Avg Return
Median
Win Rate
Best
Worst
Gap
0.44%
0.47%
52.17%
4.97%
-7.73%
1 Day
0.81%
0.70%
56.52%
12.36%
-7.44%
1 Week
-2.61%
-2.67%
36.96%
14.11%
-35.69%
2 Weeks
-1.05%
-1.12%
43.48%
25.00%
-34.78%
1 Month
-0.59%
-2.24%
48.89%
37.47%
-56.96%
Next earnings: August 6, 2026 (24 days away)
Seasonality & Day-of-Week Patterns
Monthly Seasonality
Month
Avg Return
Win Rate
Samples
Jan
-6.1%
27.3%
11
Feb
2.1%
45.5%
11
Mar
-8.5%
33.3%
12
Apr
1.0%
58.3%
12
May
-4.3%
33.3%
12
Jun
0.5%
58.3%
12
Jul
13.9%
63.6%
11
Aug
-2.8%
45.5%
11
Sep
9.4%
54.5%
11
Oct
4.8%
54.5%
11
Nov
1.5%
54.5%
11
Dec
10.3%
54.5%
11
Day-of-Week Tendencies
Day
Avg Return
Win Rate
Samples
Monday
0.11%
50.9%
536
Tuesday
-0.17%
48.2%
589
Wednesday
0.54%
50.0%
586
Thursday
0.16%
45.8%
577
Friday
-0.06%
46.7%
572
Top Institutional Holders
Institutional holder breakdown coming soon.
Total institutional ownership: 89.5%
Insider Transactions — Smart Summary
Total insider ownership: 3.0%
Founder-led management: Gaurav Shah (CEO & Director)
12-Month Insider Activity Summary
Total Filings
27
Net Value
-$523,913.71
Net Shares Change
-99,945
% of Float
-0.1%
C-Suite Filings
25
Clusters Detected
4
Key Insiders
Name
Title
Net Value
Filings
Activity
Bjork Elisabeth
+$68,500
2
2 buy
Chaudhuri Sarbani
Chief Commercial & Medical Affairs Officer
-$67,740.7
1
1 sell
Shah Gaurav
CEO
-$59,594.128
3
3 sell
Wilson Martin
General Counsel
-$14,115.034
2
2 sell
Militello John
Vice President of Finance, Treasurer, Principal Accounting Officer
-$4,240.506
2
2 sell
Transaction Clusters
Period
Filings
Insiders
Net Value
Seniority
2025-08-18 – 2025-08-27
7
4
-$73,038.682
6 C-suite
2025-11-20 – 2025-11-20
4
4
-$34,462.599
4 C-suite
2026-02-18 – 2026-02-20
6
3
-$122,040.27
6 C-suite
2026-05-11 – 2026-05-21
7
4
-$103,194.134
7 C-suite
Significant Filings
Date
Insider
Title
Net Value
Price After
2026-05-11
Chaudhuri Sarbani
Chief Commercial & Medical Affairs Officer
-$67,740.7
Transaction at $3.84, now +1.9%
2026-05-26
Shah Gaurav
CEO
-$42,496.234
Transaction at $2.39, now +63.7%
2026-05-21
Wilson Martin
General Counsel
-$1,995.268
Transaction at $3.01, now +29.7%
2026-05-21
Shah Gaurav
CEO
-$7,260.726
Transaction at $3.01, now +29.7%
2026-05-21
Militello John
Vice President of Finance, Treasurer, Principal Accounting Officer
Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Rocket Pharmaceuticals Inc
(RCKT) powered by Claude Opus — Anthropic's most capable AI model.
The analysis covers five layers:
technical analysis (near-term, medium-term, cyclical, and secular trend, momentum,
volume shelf support and resistance, breakout and breakdown signals),
qualitative analysis (business model, competitive moat, sector dynamics),
insider sentiment (buy and sell signals from executive and director transactions),
share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and
fundamental analysis (valuation, revenue growth, profit margin, earnings quality).
AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit,
stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward.
Whether you are building a long position, initiating a short, or looking for a reversal setup,
AI Consult identifies the highest-probability signal from the current trend.